exatecan: Clinical Trials

16 trials of exatecan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed. 12 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 212Completed 12
Phase 13Completed 3
Phase 31Completed 1

Follow exatecan: new trials by email Literature Review of exatecan trials Research Report on exatecan

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor
exatecan mesylate - Sarcoma
Phase 2CompletedDaiichi Sankyo2003-01-012012-05-16
Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma
exatecan mesylate - Sarcoma
Phase 2CompletedDaiichi Sankyo2003-01-012012-05-16
Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma
exatecan mesylate - Sarcoma
Phase 2CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC392002-05-012012-07-18
Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction
exatecan mesylate - Unspecified Adult Solid Tumor, Protocol Specific
Phase 1CompletedJonsson Comprehensive Cancer Center2002-05-012013-07-10
Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
exatecan mesylate, gemcitabine hydrochloride - Pancreatic Cancer
Phase 3CompletedDaiichi Sankyo2001-07-012012-05-16
DX-8951f in Treating Patients With Metastatic Stomach Cancer
exatecan mesylate - Esophageal Cancer, Gastric Cancer
Phase 2CompletedDaiichi Sankyo2001-04-012012-05-16
DX-8951f in Treating Patients With Biliary Cancer
exatecan mesylate - Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Phase 2CompletedDaiichi Sankyo2000-03-012012-05-16
DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix
exatecan mesylate - Cervical Cancer
Phase 2CompletedDaiichi Sankyo2000-01-012012-05-16
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
filgrastim, exatecan mesylate - Brain and Central Nervous System Tumors, Lymphoma
Phase 1CompletedDaiichi Sankyo1999-09-012012-05-16
DX-8951f in Treating Patients With Liver Cancer
exatecan mesylate - Liver Cancer
Phase 2CompletedDaiichi Sankyo1999-09-012012-05-16
Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer
exatecan mesylate - Fallopian Tube Cancer, Ovarian Cancer
Phase 2CompletedDaiichi Sankyo1999-07-012012-05-16
DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas
exatecan mesylate - Pancreatic Cancer
Phase 2CompletedDaiichi Sankyo371999-06-012012-05-16
Chemotherapy in Treating Women With Metastatic Breast Cancer
exatecan mesylate - Breast Cancer
Phase 2CompletedDaiichi Sankyo1999-06-012012-05-16
Chemotherapy in Treating Patients With Prostate Cancer
exatecan mesylate - Prostate Cancer
Phase 2CompletedDaiichi Sankyo1999-06-012012-05-16
Chemotherapy in Treating Patients Who Have Hematologic Cancer
exatecan mesylate - Leukemia, Myelodysplastic Syndromes
Phase 1CompletedDaiichi Sankyo1999-06-012012-05-16
DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
exatecan mesylate - Lung Cancer
Phase 2CompletedDaiichi Pharmaceuticals1999-02-012013-07-10

Conditions studied

Sarcoma (3)  ·  Carcinoma, Hepatocellular (2)  ·  Liver Neoplasms (2)  ·  Pancreatic Neoplasms (2)  ·  Adenocarcinoma Of Esophagus (1)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Astrocytoma (1)  ·  Bile Duct Neoplasms (1)  ·  Blast Crisis (1)  ·  Breast Neoplasms (1)  ·  Burkitt Lymphoma (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Central Nervous System Neoplasms (1)  ·  Choroid Plexus Neoplasms (1)

Sponsors

Daiichi Sankyo (13)  ·  Daiichi Pharmaceuticals (1)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  Jonsson Comprehensive Cancer Center (1)

Countries

United States (14)  ·  Canada (4)  ·  Germany (2)  ·  Belgium (1)  ·  Denmark (1)  ·  Finland (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Puerto Rico (1)  ·  Slovakia (1)  ·  United Kingdom (1)

Top investigators

Robert L. DeJager, MD, FACP (13)  ·  Carolyn Britten, MD (1)  ·  Nick Thatcher, PhD, FRCP (1)  ·  Peter Reichardt, MD (1)

Results publications

PMID 12114413, PMID 12871785, PMID 16133799, PMID 16983112, PMID 17336054